Xilio Therapeutics, Inc.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a XLO research report →
Companywww.xiliotx.com
Xilio Therapeutics, Inc. , a clinical-stage biotechnology company, develops immunotherapies to improve the immune system of cancer patients. Its checkpoint inhibitor program includes XTX101, a clinical-stage, tumor-selective anti-CTLA-4 mAb that is in Phase 1/2 clinical trials in patients with solid tumors.
- CEO
- Rene Russo
- IPO
- 2021
- Employees
- 64
- HQ
- Waltham, MA, US
Price Chart
Valuation
- Market Cap
- $50.50M
- P/E
- -44.08
- P/S
- 0.94
- P/B
- 19.02
- EV/EBITDA
- 2.28
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 70.69%
- Op Margin
- -78.98%
- Net Margin
- -58.52%
- ROE
- -117.24%
- ROIC
- -34.65%
Growth & Income
- Revenue
- $43.77M · 589.88%
- Net Income
- $-35,036,000 · 39.84%
- EPS
- $-4.19 · 72.54%
- Op Income
- $-41,982,000
- FCF YoY
- 70.08%
Performance & Tape
- 52W High
- $16.10
- 52W Low
- $6.47
- 50D MA
- $8.13
- 200D MA
- $9.33
- Beta
- -0.13
- Avg Volume
- 49.15K
Get TickerSpark's AI analysis on XLO
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| Apr 15, 26 | Blanchard Cheryl R | other | 10,000 |
| Apr 15, 26 | Blanchard Cheryl R | other | 0 |
| Mar 26, 26 | Shannon James Samuel | buy | 5,000 |
| Feb 13, 26 | GILEAD SCIENCES, INC. | buy | 3,739,000 |
| Dec 31, 25 | Luptakova Katarina | other | 451,885 |
| Jan 1, 26 | Luptakova Katarina | other | 16,625 |
| Jan 1, 26 | Luptakova Katarina | other | 16,625 |
| Dec 31, 25 | Brennan Kevin M. | other | 95,221 |
| Jan 1, 26 | Brennan Kevin M. | other | 5,000 |
| Jan 1, 26 | Brennan Kevin M. | other | 5,000 |
Our XLO Coverage
We haven't published any research on XLO yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate XLO Report →